Finance

Lists
DBVT:NASDAQ
DBV Technologies SA - ADR
$9.91
-0.70%
(-0.070) 1D
Oct 7, 2:19:41 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DBVT...
Open
$9.74
High
$10.05
Low
$9.64
Mkt. cap
620.38M
Avg. vol.
340.74K
Volume
327.40K
52-wk high
$26.18
52-wk low
$9.64
EPS
-$3.57
Beta
-1.04
Shares outstanding
62.88M
No. of employees
170
Open
$9.74
High
$10.05
Low
$9.64
Mkt. cap
620.38M
Avg. vol.
340.74K
Volume
327.40K
52-wk high
$26.18
52-wk low
$9.64
EPS
-$3.57
Beta
-1.04
Shares outstanding
62.88M
No. of employees
170
News stories
From web sources and news partners
Profile
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
About DBV Technologies SA - ADR
CEO-
Employees170
FoundedMar 29, 2002
Headquarters-
SectorBiotechnology
Websitedbv-technologies.com
Analyst ratings
Based on 4 analysts giving stock ratings to DBVT in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for DBVT in the last 3 months.
Highest
Current $9.91
$51.00 (+414.63%)
Average
$46.00 (+364.18%)
Lowest
$40.00 (+303.63%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sam Slutsky
LifeSci Capital
Buy
Maintained
$45.00
+354.1%
09/30/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$40.00
+303.6%
09/21/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$48.00
+384.4%
07/16/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$51.00
+414.6%
07/17/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$55.00
+455%
06/30/2026
Rajan Sharma
Goldman Sachs
Sell
Maintained
$5.81
-41.4%
04/09/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.77M
645.00K
900.00K
700.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
28.62M
32.89M
33.40M
31.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.44M
12.80M
15.30M
20.10M
Operating expense
37.05M
45.70M
48.70M
51.30M
Total operating expenses
37.05M
45.70M
48.70M
51.30M
Operating income
-34.28M
-45.05M
-47.80M
-50.60M
Other non operating income
1.00K
-1.00K
-100.00K
-
EBT including unusual items
-33.16M
-44.46M
-47.40M
-50.20M
EBT excluding unusual items
-33.16M
-44.46M
-47.40M
-50.20M
Income tax expense
-
374.00K
200.00K
200.00K
Effective tax rate
-
-0.84%
-0.42%
-0.40%
Other operating expenses
-
-
-
-
Net income
-33.16M
-44.83M
-47.60M
-50.40M
Net profit margin
-1,195.53%
-6,950.23%
-5,288.89%
-7,200.00%
Earnings per share
-
-
-
-
Interest and investment income
1.11M
597.00K
500.00K
400.00K
Interest expense
-
-
-
-
Net interest expenses
1.11M
597.00K
500.00K
400.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.49M
-44.36M
-46.90M
-50.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps